The global Afinitor drug market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factor for the growth of the market is the increase in the number of organ transplants and rising incidences of chronic diseases such as cancer. According to the US Health Resources and Services Administration, in 2020, nearly 39,000 organ transplants were performed in the US. With the increasing prevalence of chronic diseases such as kidney disease and liver disease, there is high demand for organ transplantation. Every 9 minutes, a new person is added to the transplant waiting list. Therefore, the demand for the Afinitor drugs is growing significantly which is an immunosuppressant used after the organ transplantation procedure is performed.
A full report of Afinitor Drug Market is available at: https://www.omrglobal.com/industry-reports/afinitor-drug-market
The Afinitor drug is also used for the treatment of cancer. The active substance present is known as everolimus that blocks the mammalian target of rapamycin mTOR. It forms a complex with the FKBP-12 protein which in turn, blocks the mTOR. mTOR is present inside the cell and supports cell division by blocking off the mTOR and the cancer spread slows down. This drug is used in the treatment of various cancers which include breast cancer, pancreatic neuroendocrine tumours, renal cell carcinoma, and many others. Afinitor was launched by Novartis in 2009, after the approval of the US FDA. In 2019, Novartis reported nearly $1 billion in sales of Afinitor. Many generic drugs maker have started making the generics for the drugs as the patent has expired. In December 2019, the US FDA approved the first two generics of Novartis’ cancer drug Afinitor (everolimus) by Par Pharmaceuticals and Teva Pharmaceutical Industries Ltd. Both companies gained approval for everolimus tablets in 2.5 mg, 5, mg, and 7mg doses. Teva also picked up an additional approval for the drug in a 10 mg dose.
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/afinitor-drug-market
Market Coverage
- The market number available for – 2020-2027
- Base year- 2020
- Forecast period- 2021-2027
- Segment Covered-
o By Type
o By Application
- Regions Covered
o North America
o Europe
o Asia-Pacific
o Rest of the Word
- Competitive Landscape – Novartis International AG, Teva Pharmaceuticals Industries Ltd., and more.
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominates the market in base year?
- Which segment and region will project fastest growth in the market?
- How COVID-19 impacted the market?
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Afinitor Drug Market
By Type
- 5 mg
- 5 mg
- 7 mg
- 10 mg
By Application
- Hospitals
- Drug Stores
- Others
Company Profiles
- Novartis International AG
- Teva Pharmaceuticals Industries Ltd.
This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.
